{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:32Z","timestamp":1772166512380,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immediate hypersensitivity reactions to COVID-19 vaccines have been postulated to be linked to their excipients, such as polyethylene glycol (PEG) in Pfizer Comirnaty, or polysorbate 80 and ethylenediaminetetracetic acid (EDTA) in AstraZeneca ChAdOx1-S [recombinant] (Vaxzevria). These excipients are found in a range of other products, including injectable and oral medications as well as intravenous radiocontrast media (RCM) and various cosmetic products.<\/jats:p>\n                    <jats:p>\n                      Patients with proven excipient allergy may be advised to avoid a COVID-19 vaccine containing that excipient and\/or potentially cross-reactive excipients. This may result in individual patients not receiving vaccines, especially if an alternate option is not available, and on a broader level contribute to vaccine hesitancy. We present two cases of previously confirmed EDTA anaphylaxis with positive intradermal testing, who had negative Vaxzevria vaccine in-\n                      <jats:italic>vivo<\/jats:italic>\n                      testing and subsequently tolerated the vaccine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case 1<\/jats:title>\n                    <jats:p>\n                      A patient with history of anaphylaxis to RCM and local anaesthetics (LA) had positive intradermal test (IDT) to EDTA nine years earlier. Skin testing to Vaxzeria vaccine (up to 1:10 IDT), Comirnaty vaccine (up to 1:10 IDT) and EDTA 0.3\u00a0mg\/mL IDT were negative. However, following EDTA 3\u00a0mg\/ml IDT, he developed immediate generalised urticaria without anaphylaxis. Basophil activation testing was negative to disodium EDTA, Vaxzevria and Cominarty vaccines. Given the negative in-\n                      <jats:italic>vitro<\/jats:italic>\n                      and in-\n                      <jats:italic>vivo<\/jats:italic>\n                      testing to Vaxzevria vaccine, he proceeded to Vaxzevria immunisation and tolerated both doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case 2<\/jats:title>\n                    <jats:p>A patient with history of anaphylaxis to RCM had positive skin testing to EDTA and RCM containing EDTA six years earlier. Following referral to COVID19 vaccine clinic, Vaxzevria vaccine (1:10 IDT) and Cominarty vaccine (1:10 IDT) were negative whilst EDTA was positive at 0.3\u00a0mg\/mL IDT. He subsequently tolerated both Vaxzevria vaccinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Excipient allergy does not necessarily preclude a patient from receiving a vaccine containing that excipient. Allergy testing can help identify excipient-allergic patients who may still tolerate vaccination, which is important in situations where COVID-19 vaccination options are limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-022-00665-3","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T07:03:34Z","timestamp":1646895814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy"],"prefix":"10.1186","volume":"18","author":[{"given":"Syed B.","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffith","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjae","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maverick","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Tunbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chino","family":"Yuson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Hissaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh-Thao","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"issue":"11","key":"665_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","volume":"325","author":"TT Shimabukuro","year":"2021","unstructured":"Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101\u20132.","journal-title":"JAMA"},{"issue":"2","key":"665_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jaip.2013.12.001","volume":"12","author":"PAJ Russo","year":"2014","unstructured":"Russo PAJ, Banovic T, Wiese MD, Whyte AF, Smith WB. Systemic allergy to EDTA in local anesthetic and radiocontrast media. J Allergy Clin Immunol Pract. 2014;12(2):225\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"665_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.0105-1873.2003.0128c.x","volume":"49","author":"F Soga","year":"2003","unstructured":"Soga F, Izawa K, Inoue T, Katoh N, Kishimoto S. Contact dermatitis due to disodium ethylenediamine- tetraacetic acid in cosmetics and shampoo. Contact Dermatitis. 2003;49(2):105.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"665_CR4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","volume":"9","author":"A Banerji","year":"2021","unstructured":"Banerji A, Wickner P, Saff R, Stone C Jr, Robinson L, Long A, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423\u201337.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"665_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-021-00529-2","volume":"17","author":"T Vander Leek","year":"2021","unstructured":"Vander Leek T, Chan ES, Connors L, Derfalvi B, Ellis AK, Jem U, et al. COVID-19 vaccine testing & administration guidance for allergists\/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17(1):1\u20136.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"8","key":"665_CR6","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.jaip.2021.03.002","volume":"9","author":"M Caballero","year":"2021","unstructured":"Caballero M, Krantz M, Quirce S, Phillips E, Stone C Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021;9(8):2968\u201382.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"665_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaip.2014.08.011","volume":"3","author":"JM Kelso","year":"2015","unstructured":"Kelso JM. Influenza vaccine and egg allergy: nearing the end of an evidence-based journey. J Allergy Clin Immunol Pract. 2015;3(1):140\u20131.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"665_CR8","doi-asserted-by":"crossref","unstructured":"CDC. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. MMWR Morb Mortal Wkly Rep. 2021;70(December 14\u201323, 2020):1\u20136.","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"665_CR9","first-page":"11","volume":"3","author":"M Hasija","year":"2013","unstructured":"Hasija M, Li L, Rahman N, Ausar S. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine Dev Ther. 2013;3:11\u201333.","journal-title":"Vaccine Dev Ther."},{"key":"665_CR10","unstructured":"Isovue (Iopamidol Injection) contrast product information Silver Spring, USA U.S Food and Drug Administration 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018735s057lbl.pdf."},{"issue":"9","key":"665_CR11","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","volume":"9","author":"A Wolfson","year":"2021","unstructured":"Wolfson A, Robinson L, Li L, McMahon A, Cogan A, Fu X, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9(9):3308-20.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"665_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.","journal-title":"Front Pharmacol"},{"issue":"2","key":"665_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebini","year":"2014","unstructured":"Szebini J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163\u201373.","journal-title":"Mol Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00665-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T07:13:07Z","timestamp":1646896387000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00665-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1194579\/v1","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no ethics approval sought for the investigations such as skin testing of possible allergic mechanism and subsequent management with administration of the vaccine both form part of routine clinical care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The two patients have both provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}